David Moore, MD
Family Medicine · Columbus, OHNPI 1346503349
Payments from drug & device makers
Across 226 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$681
- Vanda Pharmaceuticals Inc.$438
- Lundbeck LLC$380
- Pfizer$377
- Otsuka America Pharmaceutical, Inc.$301
- Axsome Therapeutics, Inc.$270
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$501%
- Food & beverage$3,75699%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $681 |
| Vanda Pharmaceuticals Inc. | 21 | $438 |
| Lundbeck LLC | 20 | $380 |
| Pfizer | 21 | $377 |
| Otsuka America Pharmaceutical, Inc. | 16 | $301 |
| Axsome Therapeutics, Inc. | 11 | $270 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $217 |
| Amgen | 10 | $170 |
| AstraZeneca(2 entities) | 9 | $147 |
| Exact Sciences | 4 | $98 |
| Novartis | 6 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Alkermes, Inc. | 3 | $72 |
| GSK | 3 | $62 |
| BD | 1 | $50 |
| Sanofi-aventis U.S. LLC | 1 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Novo Nordisk | 2 | $33 |
| Lilly USA, LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Indivior Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$3,806 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $71,848 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $63,544 |
| EntrestoSacubitril/Valsartan | 23 | $34,803 |
| EliquisApixaban | 20 | $31,665 |
| FarxigaDapagliflozin Propanediol | 30 | $23,695 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,071 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $12,491 |
| JanuviaSitagliptin Phosphate | 12 | $8,319 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $8,264 |
| Atrovent HfaIpratropium Bromide | 12 | $5,807 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $5,736 |
| GemtesaVibegron | 12 | $5,460 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $3,917 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 240 | $2,868 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $2,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $33 | $71,84855 claims |
| NovartisEntresto | $91 | $34,80323 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $147 | $31,95945 claims |
| PfizerEliquis | $377 | $31,66520 claims |
| GSKTrelegy Ellipta | $62 | $13,07120 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $17 | $5,46012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Columbus
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
- Robert FloreaColumbus$955K
- Bryan FeldmanColumbus$404K
- Scott MerrymanColumbus$89K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.